Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Oculis Holding Ag every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Oculis Holding Ag is a small-cap company with a market capitalization of $462M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For OCS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -20.0%, measured on 325 forecast dates between 2023-03-31 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 368 forecast dates between 2023-03-31 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, OCS included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in CHF and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
| Metric | OCS | Rank |
|---|---|---|
| Market Cap | $462M | 60/60 |
| EPS | $-6.06 | – |
| FCF/Share | $-3.47 | – |
| Metric | OCS | Rank |
|---|---|---|
| ROE | -117.8% | 33/39 |
| ROA | -97.9% | 41/43 |
| ROIC | -99.5% | 43/45 |
| Tax Rate | 0.1% | – |
| Metric | OCS | Rank |
|---|---|---|
| Current Ratio | 5.96x | 15/58 |
| D/E Ratio | 0.20x | 37/48 |
| Financial Leverage | 1.20x | 38/48 |
| Working Capital | $230M | 49/58 |
| Metric | OCS | Rank |
|---|---|---|
| Operating Cash Flow | -$214M | 48/59 |
| Free Cash Flow | -$215M | 40/50 |
| Capital Spending | -$840K | 10/50 |
| Metric | OCS | Rank |
|---|---|---|
| Operating Income | -$240M | 39/51 |
| Net Income | -$280M | 37/47 |
| R&D Expense | $170M | 51/58 |
| Metric | OCS | Rank |
|---|---|---|
| Shares Outstanding | 62M | – |
| Total Current Assets | $276M | |
| Cash & Short-term Investments | $103M | |
| Total Liabilities | $50M | |
| Short-term Debt | $44M |
Companies classified under the same SEC industry code as Oculis Holding Ag (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| OCS Oculis Holding Ag | $462M | |
| LLY Eli Lilly & Co | $1.28T | |
| JNJ Johnson & Johnson | $664.95B | |
| ABBV Abbvie Inc. | $514.78B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $288.97B | |
| ABT Abbott Laboratories | $191.15B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137.50B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $101.70B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $34.50B | |
| ZTS Zoetis Inc. | $33.93B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $26.45B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.89B | |
| ASND Ascendis Pharma A/S | $16.86B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| ELAN Elanco Animal Health Inc | $12.86B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $10.85B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | |
| TGTX Tg Therapeutics, Inc. | $9.20B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.22B | |
| CORT Corcept Therapeutics Inc | $7.87B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| ALKS Alkermes Plc. | $7.70B | |
| ABVX Abivax S.A. | $7.50B | |
| CYTK Cytokinetics Inc | $7.46B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $6.94B | |
| AXSM Axsome Therapeutics, Inc. | $6.93B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.43B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | |
| BLTE Belite Bio, Inc | $6.07B | |
| LGND Ligand Pharmaceuticals Inc | $5.98B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.64B | |
| ERAS Erasca, Inc. | $4.64B | |
| TVTX Travere Therapeutics, Inc. | $4.44B |
Oculis Holding AG (OCS) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.4 per share a year ago. These figures ...
Oculis Holding AG (OCS) has been on a downward spiral lately with significant selling pressure. After declining 21.1% over the past four weeks, the stock looks well positioned for a trend reversal as ...
This Swiss-headquartered clinical-stage biopharma concern has additional operations in the United States and Ireland, two countries where the stock has dual listings. The company's focus is developing ...
Our AI scores Oculis Holding Ag every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For OCS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -20.0%, measured on 325 forecast dates between 2023-03-31 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 368 forecast dates between 2023-03-31 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Oculis Holding Ag forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
60 issuers in our coverage, OCS included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
